bioRxiv Science⌕ Search

Biology subjects

Soltero, D.

Publications and source records attributed to Soltero, D..

2 recordsLinked to original sources

Loss of short-form Ron promotes B and T cell cooperation to prevent outgrowth of breast cancer bone metastasis

While immunotherapy has great potential to eradicate tumors, success in metastatic breast cancer is limited. Bone metastasis, the most common site for breast cancer metastasis, has been associated with weakened anti-tumor immunity, both in the bone and in other metastatic sites. Additional strategies promoting anti-tumor immunity are needed. Using the MMTV-PyMT intratibial model of breast cancer bone metastasis, we discovered that deletion of host short-form Ron (Ron SF-/-) protected against bone metastatic outgrowth by promoting strong infiltration of lymphocytes, including B cells, into tumors at the micrometastasis stage. Transcriptionally, Ron SF-/- B cells were more active and inflammatory compared to wildtype. Elimination of mature B cells (JH-/-) rescued tumor growth in Ron SF-/- mice, indicating that mature B cells were necessary for anti-tumor immunity and protection against bone metastasis. In Ron SF-/- hosts, T follicular helper (Tfh) cells were abundant in tumor-enriched regions of bone, suggesting interactions between B and T cells. B-T cell cooperation was further supported by attenuation of CD4 and CD8 T cell tumor infiltration in Ron SF-/-JH-/- hosts and, conversely, diminished B cell tumor infiltration and rescue of tumor growth in Ron SF-/- hosts lacking CD4 or CD8 T cells. B cells were not required to protect Ron SF-/- mice from lung metastasis, indicating a tissue-dependent anti-tumor role for B cells. These data support a positive feedback loop between B and T cells regulated by SF-Ron and reveal the anti-tumor potential of B cells in the bone.

cancer biology↗

ASCL1 represses a latent osteogenic program in small cell lung cancer in multiple cells of origin

ASCL1 is a neuroendocrine-lineage-specific oncogenic driver of small cell lung cancer (SCLC), highly expressed in a significant fraction of tumors. However, ~25% of human SCLC are ASCL1-low and associated with low-neuroendocrine fate and high MYC expression. Using genetically-engineered mouse models (GEMMs), we show that alterations in Rb1/Trp53/Myc in the mouse lung induce an ASCL1+ state of SCLC in multiple cells of origin. Genetic depletion of ASCL1 in MYC-driven SCLC dramatically inhibits tumor initiation and progression to the NEUROD1+ subtype of SCLC. Surprisingly, ASCL1 loss converts tumors to a SOX9+ mesenchymal/neural-crest-stem-like state that can differentiate into RUNX2+ bone tumors. ASCL1 represses SOX9 expression, as well as WNT and NOTCH developmental pathways, consistent with human gene expression data. Together, SCLC demonstrates remarkable cell fate plasticity with ASCL1 repressing the emergence of non-endodermal stem-like fates that have the capacity for bone differentiation.

cancer biology↗